Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | TLR2 | O60603 | 7/20 | 0.41 |
| ▸ | TLR1 | Q15399 | 7/20 | 0.41 |
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.37 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.35 |
| ▸ | DPP4 | P27487 | 1/20 | 0.35 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.35 |
| ▸ | SNCA | P37840 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1617550 | 0.80 | ALDH1A1 (0.47) | ALDH1A1KMT2ATLR2TLR1LMNA | |
| SCHEMBL4013915 | 0.79 | ALDH1A1 (0.34) | ALDH1A1LMNAMAPT | |
| SCHEMBL4019860 | 0.78 | ALDH1A1 (0.45) | ALDH1A1KMT2ATLR2TLR1LMNA | |
| SCHEMBL20085597 | 0.77 | ALDH1A1 (0.47) | ALDH1A1KMT2ATLR2TLR1LMNA | |
| SCHEMBL8822076 | 0.77 | ALDH1A1 (0.47) | ALDH1A1KMT2ATLR2TLR1LMNA | |
| SCHEMBL962880 | 0.76 | HTT (0.45) | ALDH1A1KMT2ATLR2TLR1LMNA | |
| SCHEMBL3745954 | 0.74 | ALDH1A1 (0.44) | ALDH1A1KMT2ATLR2TLR1LMNA | |
| SCHEMBL3433157 | 0.74 | ALDH1A1 (0.41) | ALDH1A1KMT2ATLR2TLR1LMNA | |
| SCHEMBL31463575 | 0.73 | ALDH1A1 (0.54) | ALDH1A1KMT2ALMNAMAPTTHRB | |
| SCHEMBL3752676 | 0.73 | TLR2 (0.39) | ALDH1A1KMT2ATLR2TLR1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7473699-B2 | 3-cyclyl-5-(nitrogen-containing 5-membered ring)methyl-oxazolidinone derivatives and their use as antibacterial agents | ASTRAZENECA AB (SE) | 2009-01-06 | — | — | US | disclosed |
| US-7473699-B2 | 3-cyclyl-5-(nitrogen-containing 5-membered ring)methyl-oxazolidinone derivatives and their use as antibacterial agents | ASTRAZENECA AB (SE) | 2009-01-06 | — | — | US | disclosed |
| CN-1649866-A | 3-cyclyl-5-(nitrogen-containing 5-membered ring) methyl-oxazolidinone derivatives and their use as antibacterial agents | ASTRAZENECA AB (SE) | 2005-08-03 | — | — | CN | disclosed |
| US-20050119292-A1 | 3-Cyclyl-5-(nitrogen-containing 5-membered ring)methyl-oxazolidinone derivatives and their use as antibacterial agents | ASTRAZENECA AB (SE) | 2005-06-02 | — | — | US | disclosed |
| EP-1497286-A1 | 3-CYCLYL-5-(NITROGEN-CONTAINING 5-MEMBERED RING) METHYL-OXAZOLIDINONE DERIVATIVES AND THEIR USE AS ANTIBACTERIAL AGENTS | Astrazeneca AB (SE) | 2005-01-19 | — | — | EP | disclosed |
| WO-2003072575-A1 | 3-CYCLYL-5-(NITROGEN-CONTAINING 5-MEMBERED RING) METHYL-OXAZOLIDINONE DERIVATIVES AND THEIR USE AS ANTIBACTERIAL AGENTS | ASTRAZENECA AB (SE) | 2003-09-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050119292-A1 | 3-Cyclyl-5-(nitrogen-containing 5-membered ring)methyl-oxazolidinone derivatives and their use as antibacterial agents | H1-0, NGLY1, H1-5 | ALDH1A1 2977/4885KMT2A 1038/4885TLR2 2033/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.